Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AE101 cultured allogeneic corneal endothelial cell transplantation for bullous keratopathy
jRCT2043240040Completed
- Sponsor
- ActualEyes
- Start
- Jun 2024
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of ARVN901 in bullous keratopathy (PBK), sponsored by ActualEyes. Primary endpoint: Adverse events. Started Jun 2024; status: completed.
02
Drugs
ARVN901
03
Conditions
bullous keratopathy (PBK)
Beyond the preview
Go deeper on jRCT2043240040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2043240040.